ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
8 announcements
Laurus Labs delivered record Q1FY27 revenue of ₹2,026 Cr, a 29% YoY increase, driven by robust CDMO growth. EBITDA margins expanded 700 bps YoY to 31.8% on favorable mix.
Laurus Labs delivered record quarterly revenue and EBITDA margins, driven by strong CDMO commercial supplies and recovery in the affordable medicine portfolio.
Laurus Labs delivered a strong Q1 FY27 with ₹2,026 Cr revenue (up 29% YoY), driven by robust CDMO growth. EBITDA margins expanded to 31.8% due to favorable product mix and operational leverage.
Laurus Labs Ltd reported revenue from operations of ₹2,026 Cr (+29.1% YoY) and net profit of ₹362.1 Cr (+123.9% YoY) for Q1 FY27.
Laurus Labs delivered strong Q4 FY26 results with 23% annual revenue growth and significant EBITDA margin expansion to 26.8%, driven by a transforming CDMO business and generic portfolio ramp-up.
Laurus Labs delivered a robust 23% revenue growth in FY26, pivotally shifting its mix toward CDMO which now accounts for 30% of sales while maintaining ARV leadership.
Laurus Labs delivered record FY26 results with Revenue up 23% and Net Profit surging 148%, driven by a significant 36% jump in CDMO and improved operating leverage.
Laurus Labs Ltd reported revenue from operations of ₹1,812 Cr (+5.3% YoY) and net profit of ₹282.1 Cr (+21.2% YoY) for Q4 FY26.